Fibromyalgia Treatment Market Trends Estimates High Demand by 2026 And The Key Companies Are Eli Lilly and Company, Pfizer Inc., Merck & Co., Johnson & Johnson, GlaxoSmithKline Plc., Novartis AG

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue and localized tenderness affecting individuals mentally, physically and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration and depression. Fibromyalgia symptoms can be gradually accumulated with the time or it can be done by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of Fibromyalgia antidepressants or pain medication are prescribed to treat depression, anxiety, pain, and fatigue.

Download PDF Brochure of This Busines Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1691

Fibromyalgia Treatment Market: Market Dynamics

Increasing prevalence of Fibromyalgia is expected to augment market growth. According to National Fibromyalgia and Chronic Pain Association, 2014, an estimated 210 million people in 2015, were affected with fibromyalgia syndrome, accounting for 2-4% of the total world population. Moreover, growth of the market is driven by increasing clinical trials by the manufacturers and research organizations and launch of novel diagnostics in order to reduce the burden of the disease with early and accurate disease diagnosis. For instance, in 2013, Innovative Med Concepts, LLC initiated the clinical trial for the drug candidate IMC-1, for the treatment of patients with fibromyalgia. Also, in March 2018, IQuity, a data science company launched a new blood test called Isolate Fibromyalgia, which uses RNA gene expression analysis to detect fibromyalgia, thus aiding in efficient diagnostics, which can provide early medical intervention.

Furthermore, various organizations are supporting research and development and providing accessible, affordable, and appropriate treatment which is expected to augment the market growth over the forecast period. For instance, a non-profit organization named National Fibromyalgia and Chronic Pain Association (NFMCPA) aims to build a united patient and health care community educate and execute advocacy programs regarding access to care, research, diagnosis and treatment for people suffering with chronic pain from fibromyalgia and overlapping conditions.

Fibromyalgia Treatment Market: Competitive Landscape

The key players in Fibromyalgia treatment market are focusing on developing innovative solutions to treat generalized pain associated with fibromyalgia. For instance, in October 2017, Avacen Medical launched an Avacen 100 Class II, which provides provide non-invasive, rapid whole-body treatment, using a single point of contact. Avacen treatment method is a novel concept in the chronic pain treatment that safely and non-invasively infuses heat into the circulatory system to generate muscular relaxation, thus providing an ideal drug-free and safe alternative for pain relief.

Key players operating in the global fibromyalgia treatment market include Eli Lilly and Company, Pfizer Inc., Merck & Co., Johnson & Johnson, GlaxoSmithKline Plc., Novartis AG, Sanofi S.A., AstraZeneca, and Allergan Plc.

Ask Your Queries To Our Analyst : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1691

Fibromyalgia Treatment Market: Regional Dynamics

Regional segmentation of the global fibromyalgia treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global fibromyalgia treatment market, owing to increasing incidence of fibromyalgia and to curb the economic burden associated with the disease in the U.S. According to the National Fibromyalgia Association, 2015, fibromyalgia affects an estimated 10 million people in the U.S. Moreover, according to the Community Pain Center, Fibromyalgia is responsible for a decrease in productivity by 1-2%, resulting in direct and indirect expenditures of US$ 15 billion in the U.S., thus impelling the organizations and manufacturers to launch efficient therapies, which in turn is expected to bolster the fibromyalgia treatment market in the region.

The Fibromyalgia treatment market in Europe is expected to gain significant traction, owing to the presence of support groups providing online support combined with fund raising activities to make treatments available for the patients. For instance, the Fibromyalgia Action UK improves the lives of people with fibromyalgia by increasing awareness of the condition throughout the country, thereby improving awareness and access to treatments for fibromyalgia. Also, the UK Fibromyalgia, a member of Disability Rights UK, is focused on spreading awareness regarding Fibromyalgia condition through magazines and social media accounts, as well as encourages National Health Society (NHS) and private organizations to invest in new research projects.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.